| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-09 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-07 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.18 | 6e-07 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-06 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.23 | 9e-06 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.46 | 1e-05 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |